drugset / Trial / NCT03458975

Targeted Delivery of Chemotherapy With Ultrasound and Microbublles

NCT03458975

Phase 2 Completed 7 enrolled University Hospital, Tours
RandomizedParallel-groupSingle-blindTreatment

Summary

The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US waves engender a modulation of the permeability of biological barriers amplifying hence the extravasation of drugs and/or fluorescent markers through a process known as sonoporation. In such a way, the bioavailability of the therapeutic agent is augmented only in the area where US waves are focused. The objective now is to translate this therapeutic approach to the clinic by performing a feasibility study with the development of a therapy regime optimized for hepatic metastases of colorectal cancer. In order to demonstrate the clinical feasibility of the therapeutic approach based on ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal cancer treated with monoclonal antibodies in combination with chemotherapy.

Timeline

Start
2019-10-01
Primary completion
2022-09-30
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lumason Diagnostic / imaging agent